Skip to content

Inhibrx Biosciences, Inc. INBX Operating Lease Liabilities

Operating Lease Liabilities at other companies

Rogers Corporation logo
Rogers CorporationROG
$17.5M-12.9%
Nuvation Bio logo
Nuvation BioNUVB
$2.2M-42.7%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$320K
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$28.25M+10.1%
Erasca, Inc. logo
Erasca, Inc.ERAS
$40.7M-11.6%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+385%
Enterprise value$1.42B+982%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s operating lease liabilities?
Inhibrx Biosciences, Inc. (INBX) reported operating lease liabilities of $3.5M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s operating lease liabilities changed year-over-year?
Inhibrx Biosciences, Inc.'s operating lease liabilities decreased by 40.8% year-over-year, from $5.9M to $3.5M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s operating lease liabilities?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s operating lease liabilities has grown at a 92.8% compound annual growth rate (CAGR), from $1.11M to $4.13M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.